Alpha 2.0
Login Register
» Authors » Stefan Zastrow

Stefan Zastrow

Explore the profile of Stefan Zastrow including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 53
Citations 891
Followers 0
Related Specialties
Urology
Oncology
General Medicine
Top 10 Co-Authors
Manfred P Wirth
Michael Froehner
Rainer Koch
Matthias Meinhardt
Manfred Wirth
Vladimir Novotny
Oliver W Hakenberg
Marieta Toma
Ivan Platzek
Angelika Borkowetz
Published In
Urol Int
BJU Int
Urology
Eur Urol
World J Urol
Affiliations
Soon will be listed here.
Recent Articles
1.
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
Buttner F, Winter S, Stuhler V, Rausch S, Hennenlotter J, Fussel S, et al.
Genome Med . 2022 Sep; 14(1):105. PMID: 36109798
Background: Renal cell carcinoma (RCC) is a heterogeneous disease comprising histologically defined subtypes. For therapy selection, precise subtype identification and individualized prognosis are mandatory, but currently limited. Our aim was...
2.
[Management of testosterone in advanced hormone-sensitive prostate cancer: still up to date?]
Zastrow S, Mudra T, Suttmann H
Aktuelle Urol . 2021 Sep; 53(1):37-42. PMID: 34555856
Androgen-deprivation therapy (ADT) is the standard therapy used for advanced or metastatic prostate cancer, either alone or in association with additional procedures and substances. The optimum value of testosterone postulated...
3.
External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter database
Zastrow S, Krabbe L, Wolff I, Capitanio U, Klatte T, Ecke T, et al.
Int J Clin Oncol . 2019 Sep; 25(1):145-150. PMID: 31471787
Purpose: Based on data retrieved from a comprehensive multicenter database, we externally validated a published postoperative nomogram for the prediction of disease-specific survival (DSS) in patients with papillary renal cell...
4.
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study
Dieckmann K, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, et al.
J Clin Oncol . 2019 Mar; 37(16):1412-1423. PMID: 30875280
Purpose: Previous studies suggested that serum levels of microRNA (miR)-371a-3p (so-called M371 test) have a much higher sensitivity and specificity than the classic markers of testicular germ cell tumors (GCTs)...
5.
Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy
Froehner M, Koch R, Hubler M, Heberling U, Novotny V, Zastrow S, et al.
BMC Urol . 2018 Oct; 18(1):91. PMID: 30348141
Background: Radical cystectomy bears a considerable perioperative mortality risk particularly in elderly patients. In this study, we searched for predictors of perioperative and long-term competing (non-bladder cancer) mortality in elderly...
6.
Evaluation of Transperineal Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Compared to Transrectal Systematic Biopsy in the Prediction of Tumour Aggressiveness in Patients with Previously Negative Biopsy
Borkowetz A, Renner T, Platzek I, Toma M, Herout R, Baunacke M, et al.
Urol Int . 2018 Aug; 102(1):20-26. PMID: 30149386
Objectives: We compared the transperineal MRI/ultrasound-fusion biopsy (fusPbx) to transrectal systematic biopsy (sysPbx) in patients with previously negative biopsy and investigated the prediction of tumour aggressiveness with regard to radical...
7.
Only <10% of Patients Selected for Radical Prostatectomy Reach the Competing Mortality Rate of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)
Froehner M, Koch R, Hubler M, Renner T, Borkowetz A, Zastrow S, et al.
Eur Urol Focus . 2018 Feb; 5(3):361-364. PMID: 29426695
In the Prostate Cancer Intervention Versus Observation Trial (PIVOT), surgery was not associated with lower mortality compared with observation. However, the high competing mortality rate of approximately 33% after 10...
8.
Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy
Borkowetz A, Renner T, Platzek I, Toma M, Herout R, Baunacke M, et al.
Urol Int . 2018 Jan; 100(2):155-163. PMID: 29339663
Introduction: Targeted biopsy of tumour-suspicious lesions detected in multiparametric magnetic resonance imaging (mpMRI) plays an increasing role in the active surveillance (AS) of patients with low-risk prostate cancer (PCa). The...
9.
Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival
Herout R, Graff J, Borkowetz A, Zastrow S, Leike S, Koch R, et al.
Urol Oncol . 2017 Sep; 36(1):11.e1-11.e6. PMID: 28927783
Objective: To describe the course of disease of patients surgically treated for locally recurrent renal cell carcinoma (LRRCC) after nephrectomy and to identify potential predictive factors for long-term survival. Patients...
10.
Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naïve patients
Borkowetz A, Hadaschik B, Platzek I, Toma M, Torsev G, Renner T, et al.
BJU Int . 2017 Sep; 121(1):53-60. PMID: 28921850
Objectives: To evaluate the value of multiparametric magnetic resonance imaging (mpMRI) in the detection of significant prostate cancer (PCa) and to compare transperineal MRI/ultrasonography fusion biopsy (fusPbx) with conventional transrectal...